LON:AZNAstraZeneca Share Price, Forecast & News

GBX 8,767

+237.00 (+2.78 %)

(As of 07/14/2020)

Add

Compare

Today's Range

8,436

Now: GBX 8,767▼

8,767

50-Day Range

8,201

MA: GBX 8,601.56▼

9,320

52-Week Range

83.80

Now: GBX 8,767▼

9,537.09

Volume1.32 million shs

Average Volume2.31 million shs

Market Capitalization£115.05 billion

P/E Ratio53.56

Dividend Yield2.47%

BetaN/A

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Beat the Market (BTM) Rank^™

2.2 Analyst's Opinion

Consensus Rating
AstraZeneca has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 12 buy ratings, 2 hold ratings, and 6 sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of GBX 8,392.22, AstraZeneca has a potential downside of 4.3% from its current price of GBX 8,767.
Amount of Analyst Coverage
AstraZeneca has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.4 Community Rank

Outperform Votes
AstraZeneca has received 1,605 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
AstraZeneca has received 1,766 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
AstraZeneca has received 52.39% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about AstraZeneca and other stocks. Vote “Outperform” if you believe AZN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AZN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.8 Dividend Strength

Dividend Yield
AstraZeneca pays a meaningful dividend of 2.47%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
AstraZeneca does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of AstraZeneca is 131.95%. Payout ratios above 75% are not desirable because they may not be sustainable.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AstraZeneca insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of AstraZeneca is 53.56, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 17.37.
Price to Earnings Ratio vs. Sector
The P/E ratio of AstraZeneca is 53.56, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.41.
Price to Book Value per Share Ratio
AstraZeneca has a P/B Ratio of 9.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.08 out of 5 stars

Industry, Sector and Symbol

Stock Exchange LON

Industry Drug Manufacturers - Major

Sub-IndustryN/A

SectorMedical

Current SymbolLON:AZN

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.astrazeneca.com

Phone+44-20-73045000

Debt

Debt-to-Equity Ratio161.97

Current Ratio0.82

Quick Ratio0.62

Price-To-Earnings

Trailing P/E Ratio53.56

Forward P/E Ratio22.95

P/E GrowthN/A

Sales & Book Value

Annual Sales£25.70 billion

Price / Sales4.48

Cash FlowGBX 479.05 per share

Price / Cash Flow18.30

Book ValueGBX 932.70 per share

Price / Book9.40

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees64,400

Outstanding Shares1,312,269,952

Market Cap£115.05 billion

Next Earnings DateN/A

OptionableOptionable

GBX 8,767

+237.00 (+2.78 %)

(As of 07/14/2020)

30 days | 90 days | 365 days | Advanced Chart

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

AstraZeneca (LON:AZN) Frequently Asked Questions

How has AstraZeneca's stock been impacted by COVID-19 (Coronavirus)?

AstraZeneca's stock was trading at GBX 6,955 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AZN shares have increased by 26.1% and is now trading at GBX 8,767.
View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AstraZeneca?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 6 sell ratings, 2 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AstraZeneca.

How often does AstraZeneca pay dividends? What is the dividend yield for AstraZeneca?

AstraZeneca announced a dividend on Thursday, July 30th. Stockholders of record on Thursday, August 13th will be paid a dividend of GBX 69.60 per share on Monday, September 14th. This represents a dividend yield of 0.8%. The ex-dividend date is Thursday, August 13th. The official announcement can be accessed at this link.
View AstraZeneca's dividend history.

What price target have analysts set for AZN?

20 brokerages have issued 1-year target prices for AstraZeneca's stock. Their forecasts range from GBX 6,300 to £100. On average, they expect AstraZeneca's stock price to reach GBX 8,392.22 in the next twelve months. This suggests that the stock has a possible downside of 4.3%.
View analysts' price targets for AstraZeneca.

Has AstraZeneca been receiving favorable news coverage?

News coverage about AZN stock has trended somewhat positive this week, InfoTrie reports. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AstraZeneca earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about AstraZeneca.

Who are some of AstraZeneca's key competitors?

Some companies that are related to AstraZeneca include GlaxoSmithKline (GSK), Bayer (BAYN), Dechra Pharmaceuticals (DPH), Hutchison China MediTech (HCM), Opthea (OPT), Mayne Pharma Group (MYX), Vectura Group (VEC), Medical Developments International (MVP), BEXIMCO PHARMAC/S GDR REGS (BXP), Eco Animal Health Group (EAH), Allergy Therapeutics (AGY), NanoViricides (NNVC), Trilogy International Partners (TRL), Recce Pharmaceuticals (RCE) and Vita Life Sciences (VLS).
View all competitors.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include GlaxoSmithKline (GSK), Vodafone Group (VOD), Hain Celestial Group (HAIN), NVIDIA (NVDA), Gilead Sciences (GILD), Royal Dutch Shell (RDSB), Intel (INTC), National Retail Properties (NNN), BP (BP) and Johnson & Johnson (JNJ).

Who are AstraZeneca's key executives?

AstraZeneca's management team includes the following people:

Mr. Pascal Soriot, CEO & Exec. Director (Age 60)
Mr. Marc Dunoyer, CFO & Exec. Director (Age 67)
Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 48)
Thomas Kudsk Larsen, Head of Investor Relations
Mr. Jefrey Pott, Gen. Counsel

What is AstraZeneca's stock symbol?

AstraZeneca trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How do I buy shares of AstraZeneca?

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is AstraZeneca's stock price today?

One share of AZN stock can currently be purchased for approximately GBX 8,767.

How big of a company is AstraZeneca?

AstraZeneca has a market capitalization of £115.05 billion and generates £25.70 billion in revenue each year. AstraZeneca employs 64,400 workers across the globe.

What is AstraZeneca's official website?

The official website for AstraZeneca is www.astrazeneca.com.

How can I contact AstraZeneca?

AstraZeneca's mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.

This page was last updated on 8/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings